XML 35 R37.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Quarterly Financial Information (Unaudited) (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract] |
Schedule of quarterly financial information (unaudited) | The following is a summary of the quarterly results of operations of the Company for the years ended December 31, 2013 and 2012 (unaudited):
| Quarter Ended |  | Quarter Ended |  | Quarter Ended |  | Quarter Ended
| December 31, 2013 |  | September 30, 2013 |  | June 30, 2013 |  | March 31, 2013
Consolidated Statements of Operations: |  |  |  |  |  |  |
Revenue: |  |  |  |  |  |  |
Revenue under collaborative research and development arrangements | $ | 822,217 |  |  | $ | 8,388,760 |  |  | $ | 14,311 |  |  | $ | 14,259 |
Revenue under collaborative research and development arrangements with affiliated entity | 106,250 |  |  | 106,250 |  |  | 106,250 |  |  | 106,250 |
Grants and miscellaneous revenue | 811,199 |  |  | 991,835 |  |  | 665,049 |  |  | 1,334,716 |
Total revenues | 1,739,666 |  |  | 9,486,845 |  |  | 785,610 |  |  | 1,455,225 |
Operating Expenses: |  |  |  |  |  |  |
Research and development | 6,404,005 |  |  | 5,438,405 |  |  | 4,411,082 |  |  | 5,115,112 |
General and administrative | 4,339,539 |  |  | 3,282,796 |  |  | 3,046,586 |  |  | 2,974,153 |
Gain on sale of assets | (1,000,000 | ) |  | — |  |  | (1,000,000 | ) |  | — |
Total operating expenses | 9,743,544 |  |  | 8,721,201 |  |  | 6,457,668 |  |  | 8,089,265 |
Loss from operations | (8,003,878 | ) |  | 765,644 |  |  | (5,672,058 | ) |  | (6,634,040 | )
Interest and other income, net | 8,576 |  |  | 46,787 |  |  | 37,391 |  |  | 39,460 |
Change in fair value of common stock warrants | (6,052,965 | ) |  | (34,952,210 | ) |  | (3,199,878 | ) |  | (1,427,616 | )
(Loss) Gain from investment in affiliated entity | (1,419,536 | ) |  | 3,248,926 |  |  | (2,032,051 | ) |  | (836,084 | )
Net loss | (15,467,803 | ) |  | (30,890,853 | ) |  | (10,866,596 | ) |  | (8,858,280 | )
Net loss attributable to non-controlling interest | 13,473 |  |  | 13,443 |  |  | 14,008 |  |  | 14,160 |
Net loss attributable to Inovio Pharmaceuticals, Inc. | $ | (15,454,330 | ) |  | $ | (30,877,410 | ) |  | $ | (10,852,588 | ) |  | $ | (8,844,120 | )
Loss per common share—basic and diluted: |  |  |  |  |  |  |
Net loss attributable to Inovio Pharmaceuticals, Inc. stockholders | $ | (0.07 | ) |  | $ | (0.16 | ) |  | $ | (0.06 | ) |  | $ | (0.06 | )
Weighted average number of common shares—basic and diluted | 208,509,676 |  |  | 191,956,155 |  |  | 179,954,816 |  |  | 156,155,532 |
| Quarter Ended |  | Quarter Ended |  | Quarter Ended |  | Quarter Ended
| December 31, 2012 |  | September 30, 2012 |  | June 30, 2012 |  | March 31, 2012
Consolidated Statements of Operations: |  |  |  |  |  |  |
Revenue: |  |  |  |  |  |  |
Revenue under collaborative research and development arrangements | $ | 14,296 |  |  | $ | 22,495 |  |  | $ | 20,907 |  |  | $ | 24,838 |
Revenue under collaborative research and development arrangements with affiliated entity | 142,483 |  |  | 222,484 |  |  | 106,250 |  |  | 106,250 |
Grants and miscellaneous revenue | 977,974 |  |  | 609,717 |  |  | 308,925 |  |  | 1,562,033 |
Total revenues | 1,134,753 |  |  | 854,696 |  |  | 436,082 |  |  | 1,693,121 |
Operating Expenses: |  |  |  |  |  |  |
Research and development | 4,442,841 |  |  | 4,972,319 |  |  | 4,527,086 |  |  | 4,042,579 |
General and administrative | 2,919,000 |  |  | 2,674,362 |  |  | 2,696,909 |  |  | 2,488,088 |
Gain on sale of assets | — |  |  | (500,000 | ) |  | — |  |  | (651,000 | )
Total operating expenses | 7,361,841 |  |  | 7,146,681 |  |  | 7,223,995 |  |  | 5,879,667 |
Loss from operations | (6,227,088 | ) |  | (6,291,985 | ) |  | (6,787,913 | ) |  | (4,186,546 | )
Interest and other income, net | 56,520 |  |  | 37,013 |  |  | 41,036 |  |  | 31,544 |
Change in fair value of common stock warrants | 3,049,649 |  |  | (1,113,638 | ) |  | 3,594,782 |  |  | (3,548,173 | )
Gain (Loss) from investment in affiliated entity | 2,449,615 |  |  | 736,121 |  |  | (992,373 | ) |  | (561,544 | )
Net loss | (671,304 | ) |  | (6,632,489 | ) |  | (4,144,468 | ) |  | (8,264,719 | )
Net loss attributable to non-controlling interest | 12,553 |  |  | 10,413 |  |  | 11,289 |  |  | 9,770 |
Net loss attributable to Inovio Pharmaceuticals, Inc. | $ | (658,751 | ) |  | $ | (6,622,076 | ) |  | $ | (4,133,179 | ) |  | $ | (8,254,949 | )
Loss per common share—basic and diluted: |  |  |  |  |  |  |
Net loss attributable to Inovio Pharmaceuticals, Inc. stockholders | $ | — |  |  | $ | (0.05 | ) |  | $ | (0.03 | ) |  | $ | (0.06 | )
Weighted average number of common shares—basic and diluted | 140,704,889 |  |  | 135,389,308 |  |  | 134,968,394 |  |  | 134,968,394 |

X
- Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a)-(j) -URI http://asc.fasb.org/extlink&oid=25249566&loc=d3e1280-108306 + Details
Name: | us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration